1e), and hypertrophy of cardiomyocytes (CSA) (Fig
This research aims to provide theoretical references for developing novel therapeutic strategies
Bridging the gap between diabetes and cardiovascular disease: a comparative review of different glucagon-like peptide-1 (GLP-1) agonists: efficacy, safety, and patient outcomes
While leg pain was not a primary adverse event reported in major semaglutide trials, individual experiences vary widely, and understanding the potential causes matters for your safety and comfort
Why there should be such striking differences in genetically identical individuals, in a disease caused by the same mutation, is unknown, but likely involves important epigenetic and environmental influences
doi: 10.1210/jc.2019-00008 30 GabeMBNSparre-UlrichAHPedersenMFGasbjergLSInoueABruner-OsborneHet al